Wyeth Pharmaceuticals, a division of Wyeth announced that product shipments have begun for Xyntha Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, a new recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with haemophilia A, a rare, inherited blood-clotting disorder.
The details can be read here.
No comments:
Post a Comment